Gilead Sciences' COVID-19 Treatment Earns Conditional Approval in Europe

Hospitalized coronavirus patients in the EU should find it a lot easier to access Veklury, the drug from Gilead Sciences (NASDAQ: GILD) formerly known as remdesivir. The European Commission granted conditional approval to the broad-spectrum antiviral treatment on Friday.

Now, Gilead can market Veklury throughout the EU for the treatment of COVID-19 in patients 12 years of age and older with pneumonia serious enough to require supplemental oxygen in a hospital setting.

Image source: Getty Images.

Continue reading

Source Fool.com